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CIN85 phosphorylation is essential for EGFR 
ubiquitination and sorting into multivesicular 
bodies
Barbara Schroedera,b, Subhashini Srivatsanc, Andrey Shawc, Daniel Billadeaud, 
and Mark A. McNivena,b
aDepartment of Biochemistry and Molecular Biology, bCenter for Basic Research in Digestive Diseases, and 
dDepartment of Immunology, Mayo Clinic, Rochester, MN 55905; cDepartment of Pathology and Immunology, 
Washington University School of Medicine, St. Louis, MO 63110
ABSTRACT Ubiquitination of the epidermal growth factor receptor (EGFR) by cbl and its 
cognate adaptor cbl-interacting protein of 85 kDa (CIN85) is known to play an essential role 
in directing this receptor to the lysosome for degradation. The mechanisms by which this 
ubiquitin modiﬁcation is regulated are not fully deﬁned, nor is it clear where this process oc-
curs. In this study we show that EGFR activation leads to a pronounced src-mediated tyrosine 
phosphorylation of CIN85 that subsequently inﬂuences EGFR ubiquitination. Of importance, 
phospho-CIN85 interacts with the Rab5-positive endosome, where it mediates the sequestra-
tion of the ubiquitinated receptor into multivesicular bodies (MVBs) for subsequent degrada-
tion. These ﬁndings provide novel insights into how src- kinase–based regulation of a cbl 
adaptor regulates the fate of the EGFR.
INTRODUCTION
The epidermal growth factor (EGF) receptor (EGFR) controls impor-
tant cellular processes such as cellular adhesion, migration, and pro-
liferation. Accordingly, overexpression of this receptor tyrosine ki-
nase (RTK) is associated with the development of a variety of human 
cancers (Roskoski, 2004; Sebastian et al., 2006). Therefore tight 
regulation of EGFR levels, activation, and downstream signaling 
cascades is essential. A mechanism used by cells to maintain normal 
receptor levels is deliberate control of endocytic internalization, re-
cycling, and degradation of the receptor both spatially and tempo-
rally (Zwang and Yarden, 2009).
It has been demonstrated that the cbl-mediated ubiquitination 
of the EGFR is essential and sufﬁcient for proper sorting and target-
ing to the lysosome for degradation (Ettenberg et al., 2001; Huang 
et al., 2006) but is dispensable for EGFR internalization (Huang 
et al., 2006; Pennock and Wang, 2008). Although partial ubiquitina-
tion of the receptor is believed to occur at the plasma membrane 
(Stang et al., 2000; de Melker et al., 2001), this posttranslational 
modiﬁcation is not required for internalization (Huang et al., 2007) 
nor does it appear to require internalization (de Melker et al., 2001). 
Thus ubiquitination may actually perform its receptor-targeting 
function downstream of the initial endocytic event during progres-
sion from early endosomes to late endosomes/multivesicular bod-
ies (MVBs; Ravid et al., 2004). This cbl-dependent process is aug-
mented by the action of a structural adaptor protein, cbl-interacting 
protein of 85 kDa (CIN85), which tethers cbl to the endocytic ma-
chinery in an EGF-dependent manner (Dikic, 2002). A number of 
studies have suggested that CIN85 participates in both the initial 
steps of EGFR internalization (Soubeyran et al., 2002; Schmidt et al., 
2004) and also in receptor trafﬁcking and degradation (de Melker 
et al., 2001; Kowanetz et al., 2004; Schroeder et al., 2010). Of inter-
est, it has recently been shown that knockdown of CIN85 results in 
a decrease in EGFR ubiquitination (Ronning et al., 2011), although 
the underlying mechanism has not been investigated. Of greater 
importance, it also remains unclear whether the CIN85–cbl interac-
tion is essential for receptor ubiquitination and appropriate down-
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although it is unclear whether this is a regulated process. Given that 
CIN85 contains four potential Tyr phosphorylation sites, we tested 
whether CIN85 might be Tyr phosphorylated upon EGF stimulation. 
To this end, we stimulated HuH7 cells with 50 ng/ml EGF, and we 
immunoprecipitated endogenous CIN85 at different time points 
and immunoblotted for phospho-Tyr. As shown in Figure 1A, CIN85 
is indeed Tyr phosphorylated in a stepwise manner after EGF stimu-
lation, not immediately, but at later time points (peak around 30–
60 min post EGF; Figure 1, A and B; **p < 0.05).
Because src is activated upon EGF stimulation (Oude Weernink 
et al., 1994) and is a known binding partner of the CIN85 homo-
logue CD2AP (Kirsch et al., 1999), we tested whether this kinase 
could mediate CIN85 phosphorylation. We pursued this by express-
ing either constitutively active src (srcY530F) or kinase-dead src (src 
K297M) in HeLa and HuH7 cells and then monitoring CIN85 phos-
phorylation independent of EGF stimulation. Although wt src did 
not result in detectable CIN85 phosphorylation, overexpression of 
constitutively active src induced strong CIN85 phosphorylation, 
whereas the kinase-dead form was unable to do so (Figure 1C). This 
suggests that active src alone is sufﬁcient to promote CIN85 phos-
phorylation and can mimic EGF-induced CIN85 phosphorylation. To 
conﬁrm these results, we used SYF cells (src/yes/fyn triple-knockout 
process remain nebulous and need to be deﬁned further. For ex-
ample, how does activation of the EGFR induce formation of the 
CIN85–cbl complex, what downstream signaling events stimulate 
this interaction, and where in the endocytic pathway does this oc-
cur? Finally, what are the consequences of preventing this stimu-
lated interaction on EGFR trafﬁc to the lysosome?
In this study, we report a novel EGF-induced, Tyr-based phos-
phorylation of CIN85 that is mediated by src kinase 30 min post-
stimulation, suggesting that this event occurs at a later endocytic 
compartment. Interference with the src-regulated phosphorylation 
of CIN85 results in decreased association of this adaptor with both 
Rab5 at the early endosomes and the cbl ligase. Most important, 
preventing CIN85 phosphorylation signiﬁcantly reduces ubiquitina-
tion of the EGFR and leads to its accumulation in early endosomes. 
These ﬁndings reveal a novel src–CIN85-centric signaling pathway 
that regulates EGFR trafﬁcking and subsequently its degradation.
RESULTS
CIN85 is a src substrate that is phosphorylated upon EGF 
stimulation
CIN85 plays an important role in EGFR down-regulation (Haglund 
et al., 2002; Soubeyran et al., 2002; Kowanetz et al., 2003, 2004), 
FIGURE 1: CIN85 is phosphorylated upon EGF stimulation in a src-dependent manner. (A) Representative blot showing 
EGF-induced CIN85 phosphorylation. CIN85 was immunoprecipitated from HuH7 cells stimulated with EGF for the 
indicated time points before Western blot analysis with an anti-phosphotyrosine antibody. (B) A substantial increase in 
tyrosine phosphorylation was observed by 30–60 min poststimulation and quantitated from three independent 
experiments as described in A. The pTyr signal was normalized to the amount of total precipitated CIN85 in each lane, 
and the data are represented as mean o SE. (C) Representative blot showing induction of CIN85 phosphorylation by 
overexpression of active src (srcY530F) but not kinase-dead src (srcK297M) in HeLa and HuH7 cells under full serum 
conditions. (D) Representative blot showing rescue of CIN85 phosphorylation in SYF cells by reexpression of active src 
(srcY530F) but not kinase-dead src (srcK297M).
3604 | B. Schroeder et al. Molecular Biology of the Cell
Inhibition of CIN85 phosphorylation does not affect EGFR 
endocytosis
To determine the functional relevance of CIN85 phosphorylation, 
we generated a phospho-defective CIN85 mutant and then exam-
ined its effects on EGFR endocytosis and trafﬁcking. CIN85 has 
four potential Tyr phosphorylation sites—Y10, Y109, Y271, and 
Y278—all of which were converted to phenylalanine by site-directed 
mutagenesis to produce a mutant we termed CIN85-4F (CIN85-
Y10/109/271/278F). To ensure that this CIN85 mutant is not Tyr 
phosphorylated, we coexpressed active src with either FLAG-
CIN85wt or -4F and assessed the Tyr-phosphorylation status of the 
CIN85wt and mutant. As shown in Figure 2A, CIN85wt is Tyr phos-
phorylated in the presence of active src, whereas the CIN85-4F mu-
tant is not. It is important to note that the defective phosphorylation 
of the CIN85-4F mutant is not due to impaired src binding, since the 
mutant bound equally as well to src as the wt protein (Supplemental 
Figure S1C).
To determine the functional consequences of the CIN85-4F 
phospho-mutant, we ﬁrst examined the effects of CIN85wt and -4F 
on EGFR endocytosis both by immunoﬂuorescence staining (IF) 
and biochemically. For the IF analysis, HuH7 cells expressing either 
mouse embryonic ﬁbroblasts) for rescue experiments, predicting 
that without src there would be no CIN85 phosphorylation and that 
with reexpression of active src CIN85 phosphorylation should be 
rescued. Indeed, CIN85 was not phosphorylated in control SYF 
cells, whereas its phosphorylation was restored by reexpressing ac-
tive src but not kinase-dead src (Figure 1D). Of interest, reexpression 
of wt src alone in these cells did not result in detectable CIN85 
phosphorylation, suggesting that activation of this kinase is needed. 
To test whether EGF-induced src activation might induce CIN85 
phosphorylation in SYF cells, we expressed wt src kinase in these 
cells and assessed CIN85 phosphorylation with or without EGF 
addition. As shown in Supplemental Figure S1A, CIN85 was phos-
phorylated in a src- and EGF-dependent manner, revealing an 
EGFR–src cascade that leads to CIN85 phosphorylation. We further 
conﬁrmed the src dependence of CIN85 phosphorylation by a phar-
macological approach using the src inhibitor SU6656. Compared to 
control cells treated with dimethyl sulfoxide (DMSO), the SU6656 
cells exhibited signiﬁcantly reduced CIN85 phosphorylation (Sup-
plemental Figure S1B).
Taken together, those data suggest that CIN85 is Tyr phosphory-
lated upon EGF stimulation in a src-dependent manner.
FIGURE 2: A phospho-defective CIN85 mutant, CIN85-4F, does not interfere with EGFR endocytosis. (A) Mutation of 
four key tyrosines in CIN85 (CIN85-4F) prevents phosphorylation of CIN85. FLAG-tagged CIN85wt or CIN85-4F was 
precipitated from HeLa cells coexpressing active src (srcY530F), and the CIN85 phosphorylation status was assessed by 
Western blot analysis. (B) Overexpression of CIN85-4F does not affect EGFR endocytosis. Representative images of 
RhEGF internalization in HuH7 cells expressing either CIN85wt (asterisk, top) or -4F (asterisk, bottom). Internalization 
was allowed for 15 min, and cells were acid stripped to visualize only internalized ligand. (C) Quantitation of three 
independent experiments as described in B. The data are represented as mean o SE. (D) Representative blot of a 
surface biotinylation assay used to examine the effects of CIN85wt and -4F on EGFR endocytosis. HuH7 cells expressing 
FLAG-CIN85wt or -4F were stimulated for the indicated time points; surface proteins were biotinylated and precipitated 
using streptavidin (SA)-coated beads. The amount of total and surface EGFR was assessed by Western blot analysis. 
(E) Quantitation of four independent experiments as described in D. The data are represented as mean o SE.
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CIN85wt-expressing cells, RhEGF localizes to late endosomes after 
a 1-h chase (Figure 4A, inset 2) and has trafﬁcked through this endo-
cytic step to a degradative compartment by 2 h (Figure 4A, inset 3). 
As CIN85-4F–expressing cells accumulate RhEGF in the early endo-
somes, this leads to a signiﬁcant reduction in the transport of the 
labeled ligand to the Rab7-positive late endosomal compartment 
(Figure 4, A, insets 5 and 6, and B; **p < 0.0005). In addition, accu-
mulation causes a delay in RhEGF degradation visualized by reten-
tion of the RhEGF signal even after a 2-h chase (Figure 4A, compare 
insets 3 and 6).
Because our data suggest that the CIN85–cbl complex mainly 
acts at the early endosomes and not necessarily at the initial endo-
cytic pit, we visualized the components of this complex at the place 
of action. It was previously shown that cbl indeed localizes to early 
endocytic, EGFR-positive structures and remains associated with 
the receptor throughout the endocytic route (Levkowitz et al., 1998; 
de Melker et al., 2001; Visser Smit et al., 2009). It was also reported 
that cbl preferentially localizes to the Hrs-positive subdomains of 
early endosomes (Umebayashi et al., 2008). Therefore we chose Hrs 
as an early endosomal marker for our cbl colocalization studies. As 
shown in Supplemental Figure S2a, cbl localized to Hrs-positive en-
dosomes 15–30 min after EGF.
Because it is difﬁcult to localize CIN85 to endosomal structures in 
ﬁxed cells, most likely due to the transient nature of this association, 
live-cell imaging was used to assess the localization of CIN85 on 
early endosomes. Subsequently, HeLa cells were cotransfected with 
mCherry-CIN85 and active, GFP-tagged Rab5 (GFP-Rab5Q79L) as 
performed previously (Schroeder et al., 2010). Before imaging, cells 
were stimulated with 50 ng/ml EGF for 20 min, and the images were 
acquired 25–30 min after EGF addition. As shown in Supplemental 
Figure S2B, CIN85 localized to Rab5-positive early endosomes 
under these experimental conditions. To support these morpho-
logical studies, we performed coimmunoprecipitation assays. To 
FLAG-CIN85wt or the -4F mutant were incubated with rhodamine–
EGF (RhEGF) for 20 min at 37°C, and the amount of internalized 
RhEGF was quantitated. As shown in Figure 2, B and C, expression 
of either CIN85wt or CIN85-4F did not result in any signiﬁcant in-
hibition of EGFR endocytosis. These data were conﬁrmed by sur-
face biotinylation assays showing that EGFR was internalized at 
similar levels in both CIN85wt- and mutant-expressing cells after 
short pulses of EGF (Figure 2, D and E). Taken together, these data 
show that preventing CIN85 phosphorylation does not affect EGFR 
endocytosis, and they are consistent with our previous observa-
tions that this adaptor participates in the later steps of endocytic 
trafﬁcking.
Inhibition of CIN85 phosphorylation impairs EGFR exit 
from the early endosome and delays EGFR degradation
Given that EGFR internalization is not inﬂuenced by overexpression 
of the phospho-defective CIN85-4F mutant, we examined whether 
CIN85 phosphorylation might regulate EGFR endocytic trafﬁcking. 
To this end, we monitored EGFR transport by assessing the colocal-
ization of RhEGF with early and late endosomal markers in CIN85wt- 
and mutant-expressing HuH7 cells. Early versus late endosomes 
were visualized using green ﬂuorescent protein (GFP)–Rab5 or GFP-
Rab7, respectively. As shown in Figure 3, A and B, in cells expressing 
CIN85wt, RhEGF accumulates in early endosomes within 15 min 
(Figure 3A, inset 1), exits after 45–60 min (Figure 3A, insets 2 and 3), 
and is degraded by 2 h. In contrast, CIN85-4F–expressing cells do 
not exhibit alterations in the transit of the EGFR to the early endo-
some (Figure 3A, inset 4), but instead show a signiﬁcant delay in 
EGFR trafﬁcking out of the early endosome. This leads to retention 
of RhEGF in the early endosomal compartment even after the 2-h 
chase period (Figure 3A, insets 5 and 6, B; **p < 0.0005). Consistent 
with these data, we observed a signiﬁcant delay in EGFR transit to 
late endosomes when CIN85 Tyr phosphorylation was disrupted. In 
FIGURE 3: Inhibition of CIN85 phosphorylation causes a marked retention of EGFR at the early endosome. (A) RhEGF 
trafﬁcking assay in HuH7 expressing GFP-Rab5 (green) together with either FLAG-CIN8wt or FLAG-CIN85-4F. CIN85wt 
and mutant proteins were expressed at comparable levels. Arrowheads point to the Rab5 endosomes positive for 
RhEGF, which are decreased substantially in wt-expressing cells as the ligand trafﬁcs through the endocytic pathway. In 
contrast, cells expressing the CIN85-4F mutant exhibit a marked retention of RhEGF in the Rab5 endosome. Insets 1–6 
show magniﬁcations of the boxed areas in the overview images. Bars, 10 μm. (B) Quantitation of the amount of RhEGF 
colocalizing with GFP-Rab5–positive endosomes at various time points in HuH7 cells expressing GFP-Rab5 together 
with either CIN85wt (blue line) or CIN85-4F (red line). Almost no transport of ligand from the Rab5 endosome is 
observed even after a 2-h chase. For each condition q30 cells were counted, and the data are represented as mean o SE.
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CIN85 phosphorylation is essential for EGFR ubiquitination 
and appropriate receptor sorting into MVBs
CIN85 was originally identiﬁed as a cbl-binding protein by Take 
et al. (2000), and a recent study demonstrated that a disruption of 
this interaction results in an impairment of EGFR trafﬁcking from the 
early endosome (Schroeder et al., 2010). Because expression of the 
phospho-defective CIN85-4F used in this study induces the same 
block in EGFR trafﬁc (Figure 3), we postulated that src-dependent 
phosphorylation of CIN85 might regulate the cbl interaction. To this 
end, we coexpressed hemagglutinin (HA)-cbl with either FLAG-
CIN85wt or -4F and stimulated it with 50 ng/ml EGF for 30 min, 
followed by a cbl immunoprecipitation and quantitation of associ-
ated CIN85 by Western blot. Of importance, the CIN85-4F mutant 
showed substantially less binding (^80% reduction; p < 0.0005) to 
cbl than did the wt protein (Figure 6A). We observed a similar reduc-
tion in binding by assessing the interaction of endogenous cbl with 
CIN85wt or -4F (Supplemental Figure S1D; p < 0.0005). Given that 
cbl is the major E3 ligase responsible for ubiquitination of the EGFR, 
we next tested whether impairment of CIN85 phosphorylation 
might affect EGFR ubiquitination. Subsequently, HA-ubiquitin 
(HA-Ub) was coexpressed with either CIN85wt or the -4F mutant, 
and the ubiquitination status of EGFR was assessed after stimulation 
with 50 ng/ml EGF for 30 min. Of interest, expression of the 
CIN85-4F mutant caused a signiﬁcant (^70%; p < 0.05) reduction in 
EGFR ubiquitination compared with wt-expressing cells (Figure 6B), 
suggesting that a phospho-dependent interaction between CIN85 
and cbl is essential for appropriate ubiquitination of the receptor.
Appropriate ubiquitination and trafﬁcking of the EGFR regulate 
sorting of the receptor into intraluminal vesicles (ILVs) of MVBs, an 
important step in EGFR degradation and down-regulation. Because 
both of these processes are signiﬁcantly impaired in cells expressing 
the CIN85-4F phosphorylation-defective mutant, it seemed likely that 
this end, we transfected HeLa cells with GFP-Rab5 and examined 
the interaction with endogenous CIN85 after EGF stimulation. Of 
interest, CIN85 interacts with Rab5 in an EGF-dependent manner 
(Supplemental Figure S2C; p < 0.05). Furthermore, we ﬁnd that 
this interaction is dependent on the phosphorylation status of 
CIN85, as GFP-Rab5 and FLAG-CIN85wt, but not the CIN85-4F 
mutant protein, are seen to associate in response to EGF stimula-
tion (Supplemental Figure S2D; p < 0.0005). All of these ﬁndings 
are consistent with the concept of a functional src-activated 
CIN85–cbl complex that regulates the trafﬁc of EGFR at the Rab5 
endosome.
To conﬁrm the IF-based results, we performed EGFR degrada-
tion assays in HuH7 cells expressing either CIN85wt or the phos-
pho-defective CIN85-4F mutant. Again, we observed a clear de-
lay of EGFR degradation in the mutant compared with the 
wt-expressing cells (Figure 5, A and B; p < 0.05). EGFR protein 
levels were decreased by ^90% within 90 min in CIN85wt-
expressing cells, whereas cells expressing the CIN85-4F mutant 
retained nearly 50% of their EGFR at the same time point. Be-
cause inhibition of the src-dependent phosphorylation of CIN85 
delayed EGFR degradation, we also determined the involvement 
of src in that process. To this end, we performed biochemical 
EGFR degradation assays in SYF cells with or without reexpres-
sion of wt src, expecting that reintroducing src would somehow 
restore normal rates of receptor degradation in these cells. In-
deed, reexpression of src wt into SYF cells accelerated EGFR 
degradation threefold to fourfold compared with control cells 
(Figure 5, C and D; p < 0.05). Taken together, these ﬁndings sug-
gest that the phosphorylation of CIN85 is necessary for proper 
postendocytic EGFR trafﬁcking, and impairment of CIN85 Tyr 
phosphorylation causes a delay in EGFR degradation due to re-
tention of the receptor in early endosomes.
FIGURE 4: Inhibition of CIN85 phosphorylation delays delivery of EGFR to late endosomes. (A) RhEGF trafﬁcking assay 
in HuH7 expressing GFP-Rab7 (green) as a marker for the late endosome together with either FLAG-CIN85wt or 
FLAG-CIN85-4F. CIN85wt and mutant proteins were expressed at comparable levels. Arrowheads point to the Rab7 
endosomes positive for RhEGF, which are markedly increased by 60 min after chase in wt-expressing cells but minimized 
in the CIN85 mutant–expressing cells. Insets 1–6 show magniﬁcations of the boxed areas in the overview images. Bars, 
10 μm. (B) Quantitation of the amount of RhEGF colocalizing with GFP-Rab7–positive endosomes at various time points 
in HuH7 cells expressing GFP-Rab7 together with either CIN85wt (blue line) or CIN85-4F (red line). Disruption of the 
CIN85–cbl complex caused a signiﬁcant delay in EGFR trafﬁcking to the late endosomes. For each condition q30 cells 
were counted, and the data are represented as mean o SE.
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a CIN85-short hairpin RNA (shRNA)–encod-
ing lentivirus to ensure a stable and nearly 
complete knockdown of CIN85 (Supple-
mental Figure S3A), allowing us to test 
EGFR endocytosis and trafﬁcking in the 
context of CIN85 deﬁciency. As reported 
previously (Schroeder et al., 2010), EGFR 
endocytosis was only mildly affected in 
these cells compared with cells transfected 
with a nontargeting control shRNA (Supple-
mental Figure S3, B and C). Furthermore, 
we observed a missorting of the receptor to 
the limiting membrane of enlarged endo-
somes (Supplemental Figure S3, D and E), 
as well as a delay in transport of the recep-
tor to late endosomes (Supplemental Fig-
ure S3, F and G) and a concomitant reduc-
tion in EGFR degradation (Supplemental 
Figure S3, H and I). Taken together, the 
knockdown data conﬁrm that CIN85 is im-
portant in conducting early to late endo-
somal EGFR trafﬁcking.
DISCUSSION
In this study, we provide novel insights into 
the molecular mechanisms by which the en-
docytosed EGF receptor is directed toward 
the degradative pathway upon ligand stim-
ulation. Speciﬁcally, we identify a novel 
EGF-induced, src-mediated tyrosine phos-
phorylation of the endocytic adaptor pro-
tein CIN85 (Figures 1 and 2 and Supple-
mental Figure S1, A–C). This phosphorylation 
event mediates the interaction of CIN85 
with the E3 ubiquitin ligase, cbl, and is re-
quired for appropriate EGFR ubiquitination, 
sorting, and degradation (Figures 3–6 and 
Supplemental Figure S1D).
CIN85 function: from receptor internalization 
to degradation
Previously it was shown that the activated EGFR binds to cbl, which, 
in turn, recruits CIN85 to the endocytic pit. This trimeric EGFR–cbl–
CIN85 complex was assumed to trafﬁc through the endocytic path-
way for subsequent degradation. Thus CIN85 action has been impli-
cated mainly in early stages of endocytic internalization (Haglund 
et al., 2002; Soubeyran et al., 2002).
In contrast, we observed that CIN85 appears to act largely in 
postendocytic sorting and that the src-mediated phosphorylation 
of this adaptor, which peaks at ^30–60 min after EGF stimulation, 
is particularly important for later steps of endocytic receptor trafﬁc. 
Indeed, blocking CIN85 Tyr phosphorylation has no obvious effect 
on EGFR endocytosis but instead affects the efﬁcient sorting and 
degradation of the EGFR (Figures 2–6). These observations are in 
agreement with a previous study reporting the participation of 
CIN85 in late endosomal trafﬁcking via an interaction with dynamin 
2 and Rab7 (Schroeder et al., 2010). It also conﬁrms recent obser-
vations from our lab and by others showing that RNA interference–
mediated knockdown of CIN85 does not affect EGFR endocytosis 
(Supplemental Figure S3A; Schroeder et al., 2010; Ronning et al., 
2011). Consistent with this premise, expression of a phosphoryla-
tion-deﬁcient mutant of CIN85 (CIN85-4F) resulted in retention of 
CIN85 phosphorylation could play a role in sorting of the receptor 
into ILVs of MVBs. To test the efﬁcacy of MVB sorting in the CIN85 
mutant–expressing cells, we used an approach described by Lobert 
et al. (2010) and compared EGFR sorting into MVBs in cells coex-
pressing GFP-tagged Rab5-Q79L with either CIN85wt or -4F mutant 
or control cells expressing GFP-Rab5-Q79L alone. Overexpression of 
active Rab5 is well known to induce enlargement of early endosomes 
(Stenmark et al., 1994), which facilitates resolution of the MVB lumen 
from the vesicle limiting membrane. Graphically, inhibition of CIN85 
phosphorylation greatly affected MVB sorting of the EGFR (Figure 6, 
C and D). In control (Figure 6C, inset 1) and CIN85wt-expressing cells 
(Figure 6C, inset 2), the majority of EGFR was sorted into the lumen 
of the early endosomes, whereas in CIN85-4F–expressing cells EGFR 
was missorted to the limiting membrane (Figure 6C, inset 3). Quanti-
ﬁcation revealed that MVB sorting of EGFR in cells expressing the 
phospho-defective CIN85 mutant was reduced by >50% compared 
with control cells (Figure 6D; **p < 0.0001). These data indicate that 
CIN85 phosphorylation is necessary for proper sorting of EGFR into 
MVBs for subsequent trafﬁcking to late endosomes and lysosomes 
for degradation.
The role of CIN85 in early endosomal sorting and trafﬁcking of 
the EGFR was further supported by experiments using 3T9 cells 
depleted of endogenous CIN85. These cells were transfected with 
FIGURE 5: Phosphorylation of CIN85 is required for efﬁcient degradation of EGFR. HuH7 cells 
expressing FLAG-CIN85wt or FLAG-CIN85-4F (A, B) or SYF cells with or without reexpression of 
src wt (C, D) were serum starved for 4 h in the presence of 50 μg/ml CHX and treated with 
50 ng/ml EGF plus CHX for the indicated time points. Equal amounts of each sample were 
analyzed by Western blot (A and C) and show a strong persistence of EGFR levels in cells 
expressing the mutant CIN85 (A) and an acceleration of EGFR degradation in SYF cells 
reexpressing src wt (C). (B, D) Quantitation of q4 independent EGFR degradation assays 
comparing CIN85wt- and CIN85-4F–expressing cells demonstrating an 8- to 10-fold increase in 
the retention of intact EGFR in the mutant-expressing cells. SYF cells with src wt show three- to 
fourfold faster receptor degradation compared with control cells as assessed by quantitation of 
three independent experiments. The amount of EGFR in each sample was normalized to actin, 
and the data are represented as mean o SE.
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likely in concert with Rab5 and cbl at the early endosome (Figures 
6 and Supplemental Figure S2). Identifying Rab5 as an interaction 
partner of CIN85 also underlines the importance of CIN85 at the 
early endosome. Thus this interaction could ensure that the endo-
cytosed EGFR, likely in complex with cbl and CIN85 as reported 
previously (Dikic, 2002), is recruited to the early endosome while 
being retained to maximize the ubiquitination process for subse-
quent lysosomal sorting (Supplemental Figure S4, A and B). This 
EGFR in early endosomes due to the missorting of the receptor to 
the endosomal limiting membrane (Figures 3 and 6). Of impor-
tance, depletion of CIN85 induced the same EGFR trafﬁcking de-
fects as did inhibition of CIN85 phosphorylation, supporting an 
important role of CIN85 in EGFR sorting as well as degradation 
(Supplemental Figure S3, B–I). Taken together, these data provide 
novel insights into the regulation of CIN85 action and indicate that 
this adaptor protein plays an active role in EGFR sorting, most 
FIGURE 6: Inhibition of CIN85 phosphorylation results in reduced EGFR ubiquitination and missorting of the receptor 
to the limiting endosomal membrane. (A) Representative blot of a coimmunoprecipitation assay from HeLa cells 
coexpressing HA-cbl and either FLAG-CIN85wt or FLAG-CIN85-4F that were treated with 50 ng/ml EGF for 30 min. The 
levels of coprecipitated CIN85 were normalized to that of precipitated cbl, and the average amount of cbl-bound 
CIN85-4F relative to the wt from three independent experiments is shown. (B) Representative blot of an EGFR 
ubiquitination assay in HeLa coexpressing HA-Ub and either FLAG-CIN85wt or FLAG-CIN85-4F. Cells were treated with 
50 ng/ml EGF for 30 min. The amount of HA-Ub was normalized to the amount of precipitated EGFR, and the average 
amount of ubiquitinated EGFR in CIN85-4F–expressing cells relative to wt-expressing cells from three independent 
experiments is shown. (C) IF images of EGFR sorting into MVBs in HeLa cells expressing either GFP-Rab5Q79L alone 
(control) or together with FLAG-CIN85wt or FLAG-CIN85-4F. Cells were treated with 50 ng/ml EGF for 30 min. Insets 
1–3 show higher-magniﬁcation images of the boxed areas in the overview pictures. Bars, 5 μm. (D) Quantitation of three 
independent ILV sorting assays as described in C. Localization of EGFR was assessed in >30 cells, and the data are 
represented as mean o SE.
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In addition, the data in the present study strongly support the 
concept that the CIN85–cbl interaction is required for proper EGFR 
trafﬁcking and degradation, as prevention of CIN85 phosphoryla-
tion and thus CIN85–cbl complex formation greatly affects both 
processes. This is consistent with our previous ﬁndings that disrup-
tion of the CIN85–cbl complex by overexpression of another 
CIN85 mutant defective in cbl binding (CIN85B W l Y) also causes 
retention of EGFR in early endosomes (Schroeder et al., 2010). 
Thus, interfering with the CIN85–cbl complex either by mutating 
the SH3-binding site (CIN85B W l Y) or preventing phosphoryla-
tion (CIN85-4F; Figure 2) results in the same physiological out-
come. Our ﬁndings also agree with the published role for cbl on 
the early endosome, where it controls early endosome fusion and 
exit of the EGFR from the early endosome (Ravid et al., 2004; 
Visser Smit et al., 2009). Several unanswered questions need to be 
addressed in the future, however. For example, how is the CIN85–
cbl complex targeted to the early endosome? What are the impli-
cations of CIN85 phosphorylation for EGFR-dependent signaling? 
In particular, how does phospho-CIN85 activate cbl? Does phos-
pho-CIN85 also affect cbl–EGFR binding? Answering these ques-
tions will lead to better understanding EGFR trafﬁcking and might 
help to develop new tools to speciﬁcally block distinct steps in 
EGFR trafﬁcking.
MATERIALS AND METHODS
Cell culture and transfection
HeLa and HuH7 (human hepatocellular carcinoma) cells were incu-
bated in MEM, supplemented with 10% fetal bovine serum (FBS), 
1.5 g/l sodium bicarbonate, 50 U/mg penicillin plus 50 μg/ml strep-
tomycin, 1r nonessential amino acids, and 1 mM sodium pyrophos-
phate. SYF cells were cultured in DMEM supplemented with 10% 
FBS and 50 U/mg penicillin plus 50 μg/ml streptomycin. Cells were 
transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions.
Generation of the knockdown 3T9 ﬁbroblasts
Control (ﬁreﬂy luciferase) and CIN85-speciﬁc shRNA duplexes 
(Srivatsan and Shaw, unpublished data) were cloned into the pFLRu 
lentivirus as previously described (Feng et al., 2010). Viral superna-
tants were generated in 293T cells by transfection of the lentiviral 
plasmids with Lipofectamine 2000 (Invitrogen) and the packaging 
plasmids as described (Feng et al., 2010). Pooled supernatants, har-
vested at 24 and 48 h posttransfection, were applied to 3T9 ﬁbro-
blasts with 8 μg/ml polybrene and spun at room temperature for 2 h 
at 2000 rpm. Supernatants were replaced with fresh medium imme-
diately after centrifugation. Transduction efﬁciency was assessed 
48 h later by ﬂow cytometry, and yellow ﬂuorescent protein–positive 
cells were sorted using a FACSAria II high-speed cell sorter (BD, 
Franklin Lakes, NJ).
Cells were cultured in DMEM, supplemented with 10% FBS, 
2 mM L-glutamine, 1r nonessential amino acids, and 50 U/mg peni-
cillin plus 50 μg/ml streptomycin. Cells were transfected for immu-
noﬂuorescence analysis using Lipofectamine 2000 according to the 
manufacturer’s instructions.
Protein puriﬁcation and glutathione S-transferase pull down
Glutathione S-transferase (GST) fusion proteins were expressed in 
Escherichia coli BL21 cells and puriﬁed using glutathione-coated 
beads (Amersham-Pharmacia Biotech, GE Healthcare Bio-Sciences, 
Piscataway, NJ) according to the manufacturer’s instructions. Puri-
ﬁed GST-src kinase was purchased from Cell Signaling Technology 
(Beverly, MA).
idea is also strongly supported by a recent report by Ronning et al. 
(2011) in which they demonstrated that CIN85 constitutively inter-
acts with Hrs, which led them to speculate that in this context, 
CIN85 might help in promoting assembly of ESCRT complexes to 
facilitate EGFR sorting and degradation—a concept also proposed 
by Zhang et al. (2009). Further studies will be needed to determine 
the exact mechanism by which CIN85 regulates EGFR sorting at 
early endosomes.
Because the CIN85 phosphorylation, and potentially its inter-
action with cbl, occurs 30 min after EGF, it is possible that a par-
ticipation in the initial receptor ubiquitination step is minimal. It 
does remain unclear, however, why these processes/modiﬁcations 
would even be partially initiated at the plasma membrane since 
they are not essential for EGFR internalization. From the ﬁndings 
in this study and others, we view CIN85 as a critical component of 
a positive feedback loop at the early endosome that participates 
in the activation of a cbl/EGFR ubiquitination complex (Supple-
mental Figure S4B). In this model, src-phosphorylated CIN85 
increases the Ub-ligase activity of cbl at the early endosome, poten-
tially by regulating src-mediated cbl phosphorylation as already 
shown for cbl-c (Ryan et al., 2010). This increased cbl activation 
would then promote a more complete EGFR ubiquitination that 
promotes EGFR sorting into MVBs and targeting to the lysosome for 
degradation. Loss of CIN85 phosphorylation, for example, by over-
expressing the phospho-defective CIN85-4F mutant, would cause a 
reduction in src-mediated cbl phosphorylation/activation and sub-
sequent EGFR ubiquitination, leading to receptor missorting.
The CIN85–cbl interaction regulates EGFR ubiquitination 
and sorting
As previously mentioned, several reports have implicated the 
CIN895-cbl complex in EGFR endocytosis and down-regulation, 
although it is unclear whether the CIN85–cbl interaction per se is 
essential for proper receptor ubiquitination and sorting. A previ-
ous report showed that the CIN85–cbl interaction is dispensable 
for EGFR ubiquitination (Soubeyran et al., 2002), whereas others 
reported that depletion of CIN85 results in a decrease in EGFR 
ubiquitination (Ronning et al., 2011) without providing mechanistic 
insights into how and where this effect occurs. In contrast, we ob-
served a substantial decrease in EGFR ubiquitination when the 
CIN85–cbl complex was disrupted (Figure 6). We emphasize that 
our data do not exclude the possibility that EGFR ubiquitination 
could be initiated at the plasma membrane, as there is not a com-
plete loss of this modiﬁcation upon disruption of the CIN85–cbl 
complex. However, these ﬁndings agree with other studies show-
ing that EGFR ubiquitination is not important for its internalization 
(Huang et al., 2007). In general, the timing of EGFR ubiquitination 
is still not completely deﬁned and might depend on the cell type 
and experimental conditions. For example, the discrepancy be-
tween the mentioned studies and the data presented here could 
be explained by the different time courses of the observed ubiq-
uitination, as others measured the EGFR ubiquitination proﬁle in 
HEK293T and CHO cells just 10 min after EGF stimulation com-
pared with 30 min after EGF in HeLa cells in the present study. It is 
likely, then, that the different studies observed distinct phases/
peaks of EGFR ubiquitination, as described by Pennock and Wang 
(2008). Most important, we present a mechanistic insight into how 
CIN85 could regulate EGFR ubiquitination, namely by regulating 
the EGFR–cbl interaction. Taken together, our ﬁndings suggest 
that the CIN85–cbl complex contributes signiﬁcantly toward the 
second wave of EGFR ubiquitination that occurs downstream of 
the initial ubiquitination in the endocytic event.
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Pharmacological inhibition of src
Cells were pretreated with 5–10 μM SU6656 or DMSO as control for 
2 h before immunoprecipitation of CIN85 for further analysis.
Immunoprecipitation
HeLa cells were plated in 100-mm Petri dishes and grown to 70–90% 
conﬂuence. The cells were serum starved for 16 h before adding 
EGF (50 ng/ml) for the indicated time points. Cell lysates were col-
lected either in hypotonic lysis buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH 7.5, 10 mM NaCl, 1 mM KH2PO4, 
5 mM NaHCO3, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM EDTA, 10 mM 
sodium pyrophosphate, 1 mM Na3VO4, protease inhibitors) or RIPA 
buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, protease inhibitors), sonicated, and centri-
fuged for 10 min at 14,000 rpm at 4°C. Between 500 and 800 μg of 
lysate was added to 5 μg of antibody and incubated for 2 h at 4°C. 
Antibody-bound complexes were precipitated by adding protein 
A– or G–coated beads (Sigma-Aldrich [St. Louis, MO] and Santa 
Cruz Biotechnology [Santa Cruz, CA], respectively) for 1 h at 4°C, 
washed ﬁve times, and subjected to Western blot analysis.
EGFR ubiquitination
HeLa cells were cotransfected with HA-ubiquitin (HA-Ub) and 
CIN85wt or mutants as indicated, serum starved overnight, and 
then stimulated with 50 ng/ml EGF for the indicated time points. 
Cells were lysed in a NP-40/N-ethylmaleimide (NEM) buffer (30 mM 
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 4 mM EDTA, pH 8, 10 mM 
NaF, 1 mM Na3VO4, 1 mM NEM, protease inhibitors), sonicated, 
and centrifuged for 10 min at 14,000 rpm at 4°C. From 0.5 to 1 mg 
of lysate was added to 5 μg of EGFR antibody and immune precipi-
tated as described earlier.
Surface biotinylation after EGF stimulation
EGFR surface biotinylation assays were performed as described pre-
viously (Schroeder et al., 2010).
Immunoﬂuorescence, image acquisition, and manipulation
Indirect immunoﬂuorescence, image acquisition, and manipulations 
were performed as described previously (Schroeder et al., 2010).
RhEGF uptake, quantiﬁcation, and statistical analysis
RhEGF trafﬁcking assays and their quantitation were performed 
as described in Schroeder et al. (2010). Brieﬂy, cells were serum 
starved overnight in low serum medium (0.2% FBS), pretreated 
with 50 μg/ml cycloheximide (CHX) for 1 h at 37°C, and then in-
cubated with 100 ng/ml RhEGF plus CHX at 4°C for 45 min, 
pulsed for 15 min at 37°C to allow endocytosis, and then washed 
and chased for the indicated time points with low serum medium 
plus CHX. Cells were ﬁxed and subjected to immunoﬂuorescence 
analysis.
MVB sorting and quantitation
HeLa cells were cotransfected with GFP-tagged, constitutively ac-
tive Rab5 (GFP-Rab5Q79L) and either FLAG-CIN85wt or FLAG-
CIN85-4F, serum starved overnight, and then stimulated with 
50 ng/ml EGF for 30 min. Endogenous EGFR was stained with an 
EGFR antibody, and the expressed proteins were detected using 
a FLAG antibody. For quantitation, each Rab5-positive structure 
that had a clear distinction between the lumen and the limiting 
membrane was taken into account. Under each experimental con-
dition, the localization of EGFR in either the lumen or the limiting 
membrane of the Rab5 structure was assessed. For each condition 
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